AbbVie Inc. (ABBV) Free cash flow
- Free cash flow · 12 months (USD): Value $18.21B; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 28.28%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $18.21B | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $19.51B − $1.30B ≈ $18.21B |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 28.28% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $18.21B ÷ $64.39B × 100 ≈ 28.28% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $19.51B | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 3.09× | Operating cash flow / net income. Period ending 2026-06-30. $19.51B ÷ $6.31B ≈ 3.09× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 19.51B USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 1.30B USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 18.21B USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 64.39B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | |
| Net income | 6.31B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.21B | (m) | $19.51B | $1.30B | (m) | $64.39B | (m) | $6.31B | (m) | (m) | 28.28% | 3.09× |
| 2026-03-31 | $19.98B | (m) | $21.22B | $1.24B | (m) | $62.82B | (m) | $3.63B | (m) | (m) | 31.81% | 5.84× |
| 2025-12-31 | $17.82B | (m) | $19.03B | $1.21B | (m) | $61.16B | (m) | $4.23B | (m) | (m) | 29.13% | 4.50× |
| 2025-09-30 | $19.68B | (m) | $20.86B | $1.18B | (m) | $59.64B | (m) | $2.39B | (m) | (m) | 33.00% | 8.74× |
| 2025-06-30 | $18.24B | (m) | $19.28B | $1.04B | (m) | $58.33B | (m) | $3.76B | (m) | (m) | 31.27% | 5.12× |
| 2025-03-31 | $15.38B | (m) | $16.40B | $1.02B | (m) | $57.37B | (m) | $4.20B | (m) | (m) | 26.82% | 3.91× |
| 2024-12-31 | $17.83B | (m) | $18.81B | $974.00M | (m) | $56.33B | (m) | $4.28B | (m) | (m) | 31.65% | 4.40× |
| 2024-09-30 | $15.62B | (m) | $16.51B | $888.00M | (m) | $55.53B | (m) | $5.12B | (m) | (m) | 28.13% | 3.22× |
| 2024-06-30 | $17.78B | (m) | $18.64B | $858.00M | (m) | $55.00B | (m) | $5.34B | (m) | (m) | 32.33% | 3.49× |
| 2024-03-31 | $21.89B | (m) | $22.69B | $795.00M | (m) | $54.40B | (m) | $5.99B | (m) | (m) | 40.24% | 3.79× |
| 2023-12-31 | $22.06B | (m) | $22.84B | $777.00M | (m) | $54.32B | (m) | $4.86B | (m) | (m) | 40.62% | 4.70× |
| 2023-09-30 | $24.73B | (m) | $25.51B | $785.00M | (m) | $55.14B | (m) | $6.51B | (m) | (m) | 44.85% | 3.92× |
| 2023-06-30 | $24.80B | (m) | $25.54B | $743.00M | (m) | $56.02B | (m) | $8.69B | (m) | (m) | 44.27% | 2.94× |
| 2023-03-31 | $23.52B | (m) | $24.23B | $708.00M | (m) | $56.74B | (m) | $7.58B | (m) | (m) | 41.45% | 3.19× |
| 2022-12-31 | $24.25B | (m) | $24.94B | $695.00M | (m) | $58.05B | (m) | $11.84B | (m) | (m) | 41.77% | 2.11× |
| 2022-09-30 | $21.92B | (m) | $22.59B | $669.00M | (m) | $57.82B | (m) | $13.41B | (m) | (m) | 37.91% | 1.68× |
| 2022-06-30 | $22.21B | (m) | $22.92B | $709.00M | (m) | $57.35B | (m) | $12.64B | (m) | (m) | 38.73% | 1.81× |
| 2022-03-31 | $22.05B | (m) | $22.81B | $761.00M | (m) | $56.73B | (m) | $12.48B | (m) | (m) | 38.87% | 1.83× |
| 2021-12-31 | $21.99B | (m) | $22.78B | $787.00M | (m) | $56.20B | (m) | $11.54B | (m) | (m) | 39.13% | 1.97× |
| 2021-09-30 | $21.68B | (m) | $22.56B | $879.00M | (m) | $55.17B | (m) | $7.53B | (m) | (m) | 39.29% | 2.99× |
| 2021-06-30 | $19.57B | (m) | $20.45B | $879.00M | (m) | $53.73B | (m) | $6.66B | (m) | (m) | 36.43% | 3.07× |
| 2021-03-31 | $17.79B | (m) | $18.65B | $861.00M | (m) | $50.20B | (m) | $5.16B | (m) | (m) | 35.44% | 3.62× |
| 2020-12-31 | $16.79B | (m) | $17.59B | $798.00M | (m) | $45.80B | (m) | $4.62B | (m) | (m) | 36.66% | 3.81× |
| 2020-09-30 | $15.33B | (m) | $16.01B | $682.00M | (m) | $40.65B | (m) | $7.38B | (m) | (m) | 37.70% | 2.17× |
| 2020-06-30 | $14.12B | (m) | $14.73B | $619.00M | (m) | $36.23B | (m) | $6.96B | (m) | (m) | 38.96% | 2.12× |
| 2020-03-31 | $13.55B | (m) | $14.12B | $570.00M | (m) | $34.06B | (m) | $8.44B | (m) | (m) | 39.79% | 1.67× |
| 2019-12-31 | $12.77B | (m) | $13.32B | $552.00M | (m) | $33.27B | (m) | $7.88B | (m) | (m) | 38.39% | 1.69× |
| 2019-09-30 | $12.93B | (m) | $13.44B | $512.00M | (m) | $32.87B | (m) | $3.25B | (m) | (m) | 39.34% | 4.13× |
| 2019-06-30 | $12.77B | (m) | $13.41B | $640.00M | (m) | $32.62B | (m) | $4.12B | (m) | (m) | 39.14% | 3.26× |
| 2019-03-31 | $13.17B | (m) | $13.80B | $626.00M | (m) | $32.65B | (m) | $5.36B | (m) | (m) | 40.35% | 2.57× |
| 2018-12-31 | $12.79B | (m) | $13.43B | $638.00M | (m) | $32.75B | (m) | $5.69B | (m) | (m) | 39.05% | 2.36× |
| 2018-09-30 | $11.92B | (m) | $12.62B | $697.00M | (m) | $32.19B | (m) | $7.57B | (m) | (m) | 37.04% | 1.67× |
| 2018-06-30 | $10.82B | (m) | $11.37B | $541.00M | (m) | $30.95B | (m) | $6.45B | (m) | (m) | 34.98% | 1.76× |
| 2018-03-31 | $9.95B | (m) | $10.50B | $553.00M | (m) | $29.61B | (m) | $6.38B | (m) | (m) | 33.60% | 1.65× |
| 2017-12-31 | $9.43B | (m) | $9.96B | $529.00M | (m) | $28.22B | (m) | $5.31B | (m) | (m) | 33.42% | 1.88× |
| 2017-09-30 | $8.46B | (m) | $8.92B | $461.00M | (m) | $27.27B | (m) | $6.65B | (m) | (m) | 31.01% | 1.34× |
| 2017-06-30 | $6.65B | (m) | $7.10B | $448.00M | (m) | $26.71B | (m) | $6.62B | (m) | (m) | 24.90% | 1.07× |
| 2017-03-31 | $6.56B | (m) | $7.01B | $453.00M | (m) | $26.22B | (m) | $6.31B | (m) | (m) | 25.03% | 1.11× |
| 2016-12-31 | $6.56B | (m) | $7.04B | $479.00M | (m) | $25.64B | (m) | $5.95B | (m) | (m) | 25.59% | 1.18× |
| 2016-09-30 | $6.95B | (m) | $7.46B | $510.00M | (m) | $25.24B | (m) | (m) | (m) | (m) | 27.55% | (m) |
| 2016-06-30 | $7.64B | (m) | $8.16B | $524.00M | (m) | $24.75B | (m) | (m) | (m) | (m) | 30.86% | (m) |
| 2016-03-31 | $7.57B | (m) | $8.08B | $508.00M | (m) | $23.78B | (m) | (m) | (m) | (m) | 31.84% | (m) |
| 2015-12-31 | $7.00B | (m) | $7.54B | $532.00M | (m) | $22.86B | (m) | (m) | (m) | (m) | 30.64% | (m) |
| 2015-09-30 | $4.45B | (m) | $4.99B | $540.00M | (m) | $21.91B | (m) | (m) | (m) | (m) | 20.33% | (m) |
| 2015-06-30 | $4.03B | (m) | $4.63B | $593.00M | (m) | $20.99B | (m) | (m) | (m) | (m) | 19.21% | (m) |
| 2015-03-31 | $3.89B | (m) | $4.51B | $620.00M | (m) | $20.44B | (m) | (m) | (m) | (m) | 19.03% | (m) |
| 2014-12-31 | $2.94B | (m) | $3.55B | $612.00M | (m) | $19.96B | (m) | (m) | (m) | (m) | 14.71% | (m) |
| 2014-09-30 | $4.76B | (m) | $5.37B | $610.00M | (m) | $19.62B | (m) | (m) | (m) | (m) | 24.27% | (m) |
| 2014-06-30 | $4.82B | (m) | $5.38B | $563.00M | (m) | $19.26B | (m) | (m) | (m) | (m) | 25.03% | (m) |
| 2014-03-31 | $5.16B | (m) | $5.70B | $540.00M | (m) | $19.02B | (m) | (m) | (m) | (m) | 27.14% | (m) |
| 2013-12-31 | $5.78B | (m) | $6.27B | $491.00M | (m) | $18.79B | (m) | (m) | (m) | (m) | 30.74% | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $6.01B | (m) | $6.34B | $333.00M | (m) | $18.38B | (m) | (m) | (m) | (m) | 32.71% | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $5.89B | (m) | $6.25B | $356.00M | (m) | $17.44B | (m) | (m) | (m) | (m) | 33.77% | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |